Skip to content

Effects of a Goal-directed Hemodynamic Therapy Driven by ECOM on Morbidity and Mortality After Cardiac Surgery?

Does Goal-directed Hemodynamic Therapy Driven by Endotracheal Cardiac Output Monitoring System During Surgical Intervention Reduce Hospital Stay and Major Adverse Cardiac Events Following Cardiac Surgery?

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01535716
Acronym
ECOMIII
Enrollment
100
Registered
2012-02-20
Start date
2012-02-01
Completion date
2013-02-01
Last updated
2026-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Surgery With Cardiopulmonary Bypass

Brief summary

Goal-directed hemodynamic and fluid optimizations are shown to be a key factor of the medical care during anesthesia.According to medical literature, goal-directed fluid and hemodynamic optimizations are more efficient when based on the dynamic parameters than when based on the statics ones, and the major dynamic criteria is the cardiac output. Unfortunately, transpulmonary thermodilution, the device considered as "The gold standard" to evaluate cardiac output is associated with many complications.Furthermore, devices commercialized in the past decade were not able to replace the transpulmonary thermodilution. As all monitoring devices aren't reliable enough to be widely used in practice they are left aside in benefits of the clinical evaluation. Even though, hemodynamic optimization based on the analysis of several clinical parameters seems to guarantee good cares thanks to a favorable benefits/risks balance, it could be improved by new plug and play mini-invasive systems. In the investigators opinion, the ECOM system seems able to provide a monitoring tool which responds to all the expectations of a modern hemodynamic monitoring device. It uses a well known technique, the bioimpedance. The investigators suppose this device should be more efficient than the one that has been used before. Indeed, as the system is build on the endotracheal tube, it comes closer to the aorta, where all the measures are made, and the recorded signal should be less affected by the passage through the surrounding tissues. This randomized and controlled trial will study Patients scheduled for elective coronary surgery with cardiopulmonary bypass. The purpose of this trial is to evaluate the benefits of an intraoperative goal-directed hemodynamic therapy based on the ECOM cardiac output measure on mortality and major postoperative cardiac morbidity after coronary surgery, when compared with a standard management strategy. Patients will be allocated into control and ECOM groups, of 50 peoples each. The standard management strategy, applied to the control group, will be set and led by the attending anesthetist, based on the analysis of further clinical parameters. The ECOM Group will face the hemodynamic optimization strategy led by the ECOM evaluation of cardiac output and stroke volume variation. The main hypothesis is that the hemodynamic strategy led by the ECOM cardiac output measure will reduce mortality and morbidity after cardiac surgery.

Interventions

BEHAVIORALhemodynamic optimization strategy driven by the ECOM

goal directed hemodynamic therapy is based on the ECOM evaluation of stroke volume variation (SVV) \& cardiac index (CI). goals: * SVV \< 11% * IC \> 2,2 ml/min/m² During the anesthesia

BEHAVIORALstandard management strategy

goal directed hemodynamic therapy will be set and performed by the attending anesthetist, based on the analysis of further clinical parameters: Standard monitoring : heart rate, saturation index * Diuresis \> 0,5ml/kg/h * Blood pressure , PAM \> 65 mmHg * Pulse pressure variation * CVP 8 to 12 cmH20 * Visual aspect of the heart * Overload signs During the anesthesia

Sponsors

University Hospital, Caen
Lead SponsorOTHER
CONMED Corporation
CollaboratorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Any man or woman * Over 18 year-old * After obtaining written informed consent * Scheduled for elective coronary surgery with CPB

Exclusion criteria

* Emergency surgery (\< 24h) * Combined cardiac surgery * Patients \< 18 years-old and/or unable to give informed consent * Patients who refuse to give informed consent * Pregnancy * PVC allergy

Design outcomes

Primary

MeasureTime frame
length of hospital stayData collected at the exit of hospital or at death, if during hospital stay.patients will be followed for the duration of hospital stay, an expected average of 10 days. expected before 1 month

Secondary

MeasureTime frame
Number of major adverse cardiac events during stay in hospitalData collected at the exit of ICU, at the exit of hospital or at death if during hospital stay.patients will be followed for the duration of hospital stay, an expected average of 10 days.Up to 1 month
Length of stay in ICUat the exit of ICU or at death, if during hospital stay.expected before 1 month
In-hospital mortalityat the end of the study. up to 12 month
Number of patients with Major adverse cardiac events during in-hospital stay.at the end of the study. Up to 12 month

Countries

France

Contacts

STUDY_DIRECTORJean-Luc Fellahi

EA3212: groupe coeur et ischémie

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 3, 2026